Virtuoso Therapeutics is a biopharmaceutical company advancing a pipeline of novel bispecific antibodies to treat cancer. Using a differentiated approach to antibody engineering, the company designs molecules intended to overcome the limitations of existing therapies and to address major hurdles facing emerging classes of oncology treatments. - View it on GitHub